Background: Up to 35% of individuals diagnosed with epilepsy proceed to develop pharmacoresistant epilepsy, leading to persistent uncontrolled seizure activity that can directly, or indirectly, significantly degrade an individual's quality of life. The factors underlying pharmacoresistance are unclear, but it has been hypothesised that repeated ictogenic activity is conducive to the development of a more robust epileptogenic network. To ensure that the most effective treatment choices are made and ictogenic activity is minimised, accurate outcome modelling at the point of diagnosis is key. Objectives: This review therefore aims to identify demographic, clinical, physiological (e.g. EEG), and imaging (e.g. MRI) factors that may be predictive of treatment outcomes in patients with newly diagnosed epilepsy (NDE). Data sources, study eligibility criteria, participants, and interventions: MEDLINE and EMBASE were searched for prediction models of treatment outcomes in patients with newly diagnosed epilepsy and any non-surgical treatment plan. Study appraisal and synthesis methods: Study characteristics were extracted and subjected to assessment of risk of bias (and applicability concerns) using the PROBAST tool. Prognostic factors associated with treatment outcomes are reported. Results: After screening, 48 models were identified in 32 studies, which generally scored low for concerns of applicability, but universally high for susceptibility to bias. Outcomes reported were heterogenous, but fit broadly into four categories: pharmacoresistance, short-term treatment response, seizure remission, and mortality. Prognostic factors were also heterogenous, but the predictors that were commonly significantly associated with outcomes were those related to seizure characteristics (semiology), epilepsy history, and age at onset. ASM response was often included as a prognostic factor, potentially obscuring factor relationships at baseline. Conclusions: Currently, outcome prediction models for NDE demonstrate a high risk of bias. Model development could be improved with a stronger adherence to recommended TRIPOD practices, and by avoiding including response to treatment as a prognostic factor. Implications of key findings: This review identified semiology, epilepsy history, and age at onset as factors associated with treatment outcome prognosis, suggesting that future prediction model studies should focus on these factors in their models. Furthermore, we outline actionable changes to common practices that are intended to improve the overall quality of prediction model development in NDE. Keywords: newly diagnosed epilepsy, seizures, prognosis, intractability, outcomes, treatment

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors